1. Gossamer Bio will present at several investor conferences in September. 2. Conferences include Cantor Global, Wells Fargo, and H.C. Wainwright. 3. Gossamer focuses on seralutinib for treating pulmonary arterial hypertension. 4. The conferences aim to enhance investor relations and company visibility. 5. Presentations will include fireside chats and one-on-one meetings.
Investors typically respond positively to company visibility at key conferences, as seen historically with biotech firms increasing their valuations after significant presentations.
The presentations could showcase Gossamer Bio's growth potential, affecting market perception and stock movement.
The outcomes of the conferences could quickly influence investor sentiment and stock price in the upcoming months.
Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the following investor conferences in September.
Cantor Global Healthcare Conference |
|
|
|
Date / Time: |
September 3rd, at 9:10 AM ET |
Format: |
Fireside Chat & 1x1's |
Location: |
New York, NY |
Webcast Link: |
|
Wells Fargo Healthcare Conference |
|
|
|
Date / Time: |
September 4th |
Format: |
1x1's |
Location: |
Boston, MA |
H.C. Wainwright 27th Annual Global Healthcare |
|
|
|
Date / Time: |
September 9th, at 8:00 AM ET |
Format: |
Fireside Chat & 1x1's |
Location: |
New York, NY |
About Gossamer Bio
Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250829692001/en/
For Investors and Media
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com